Related Experiment Video
Updated: Aug 5, 2026
05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
[Changes in obesity management: The clinician's perspective]
1Service d'Endocrinologie - Diabétologie - Nutrition, Hôpital Rangueil, Centre Spécialisé de l'Obésité, Occitanie Ouest, 31432 Toulouse, France.
Biologie Aujourd'Hui
|July 31, 2026
Summary
Obesity affects one in five French people, with prevalence doubling since 1997. New definitions and treatments like incretin agonists offer hope but require comprehensive, sustainable lifestyle support for long-term success.
Area of Science:
- Endocrinology
- Public Health
- Metabolic Diseases
Background:
- Obesity prevalence in France has doubled since 1997, affecting nearly 20% of the population.
- Defined as a chronic disease, obesity leads to mechanical, metabolic, and psychosocial complications, increasing cancer risk.
- A new 2025 definition incorporates BMI, organ damage, and functional limitations for personalized care.
Purpose of the Study:
- To review the evolving definition and management of obesity in France.
- To evaluate the role and limitations of incretin agonists in obesity treatment.
- To emphasize the need for comprehensive, sustainable care plans beyond pharmacotherapy.
Main Methods:
- Review of French High Authority for Health (HAS) recommendations (2022, 2024).
- Analysis of the clinical definition and phenotyping of obesity.
- Evaluation of second-line pharmacological treatments, specifically incretin agonists (GLP-1, GLP-1/GIP).
Main Results:
- Incretin agonists achieve >10% weight loss and improve metabolic comorbidities but have side effects and adherence issues.
- Comprehensive care involves lifestyle modifications (nutrition, physical activity, psychological support) and therapeutic education.
- Treatment goals extend beyond weight loss to include comorbidity management, quality of life, and mobility.
Conclusions:
- Obesity management requires a stepwise approach, integrating lifestyle changes, psychological support, and pharmacotherapy.
- Incretin agonists are effective but must be part of a sustainable plan to mitigate side effects and ensure long-term benefits.
- Personalized phenotyping and a holistic treatment strategy are crucial for optimizing outcomes in obesity care.
Related Concept Videos
01:24Obesity
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...